METHODS AND COMPOSITIONS FOR TREATING CANCER
First Claim
Patent Images
1. A method for the treatment of a cancer in a mammal comprising administering a therapeutically effective amount of at least one 17α
- -hydroxylase/C17,20-lyase inhibitor and a therapeutically effective amount of at least one additional therapeutic agent to a patient having a cancer;
wherein the 17α
-hydroxylase/C17,20-lyase inhibitor comprises a compound of the formula (I) or an analog, a derivative, a metabolite or a pharmaceutically acceptable salt thereof, wherein R represents a hydrogen, or an acyl group having 1-4 carbons.
5 Assignments
0 Petitions
Accused Products
Abstract
Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17α-hydroxylase/C17,20-lyase inhibitor, such as abiraterone acetate (i.e., 3β-acetoxy-17-(3-pyridyl)androsta-5,16-diene), in combination with at least one additional therapeutic agent such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising a 17α-hydroxylase/C17,20-lyase inhibitor, and at least one additional therapeutic agent, such as an anti-cancer agent or a steroid.
-
Citations
36 Claims
-
1. A method for the treatment of a cancer in a mammal comprising administering a therapeutically effective amount of at least one 17α
- -hydroxylase/C17,20-lyase inhibitor and a therapeutically effective amount of at least one additional therapeutic agent to a patient having a cancer;
wherein the 17α
-hydroxylase/C17,20-lyase inhibitor comprises a compound of the formula (I) or an analog, a derivative, a metabolite or a pharmaceutically acceptable salt thereof,wherein R represents a hydrogen, or an acyl group having 1-4 carbons. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)
- -hydroxylase/C17,20-lyase inhibitor and a therapeutically effective amount of at least one additional therapeutic agent to a patient having a cancer;
-
22. A method for treating a patient having a refractory prostate or breast cancer who is currently receiving at least one treatment for cancer, the method comprising administering a therapeutically effective amount of at least one 17α
- -hydroxylase/C17,20-lyase inhibitor in addition to the at least one treatment the patient is currently receiving, wherein the 17α
-hydroxylase/C17,20-lyase inhibitor comprises a compound of the formula (I) or an analog, a derivative, a metabolite or pharmaceutically acceptable salt thereof,wherein R represents a hydrogen, or an acyl group having 1-4 carbons. - View Dependent Claims (23, 24, 25, 26)
- -hydroxylase/C17,20-lyase inhibitor in addition to the at least one treatment the patient is currently receiving, wherein the 17α
-
27. A pharmaceutical composition for the treatment of a cancer in a mammal comprising a therapeutically effective amount of at least one 17α
- -hydroxylase/C17,20-lyase inhibitor; and
at least one additional therapeutic agent;
wherein the 17α
-hydroxylase/C17,20-lyase inhibitor comprises a compound of the formula (I) or an analog, a derivative, a metabolite or a pharmaceutically acceptable salt thereof,wherein R represents a hydrogen, or an acyl group having 1-4 carbons. - View Dependent Claims (28, 29, 30, 31)
- -hydroxylase/C17,20-lyase inhibitor; and
-
32. A pharmaceutical composition for the treatment of a cancer in a mammal comprising a therapeutically effective amount of abiraterone acetate;
- and a therapeutically effective amount of a steroid, wherein the composition is suitable for oral administration.
- View Dependent Claims (33, 34, 35, 36)
Specification